SeaStar Medical and LMF Acquisition Opportunities have reported data from the SCD 005 clinical study of the use of SeaStar Medical’s Selective Cytopheretic Device (SCD) in treating Covid-19 patients suffering from multiple organ failure and admitted to the intensive care unit (ICU).

A cell-directed, patented, extracorporeal immunomodulator, the SCD has been designed to address hyperinflammation with selective targeting of activated neutrophils and monocytes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The multi-centre pilot study has been designed to evaluate the SCD’s safety and efficacy in 22 Covid-19 patients either with acute kidney injury (AKI) or acute respiratory distress syndrome (ARDS).

The company stated that the SCD was integrated into a continuous renal replacement therapy (CRRT) blood circuit in the study.

During the study, patients were treated for up to 10 days, with a new SCD placed in the circuit every 24 hours or as required.

Reductions were observed in activated neutrophils and monocytes, which in turn led to a reduction in proinflammatory cytokines and improved clinical outcomes in patients.

SeaStar Medical said that subjects who received SCD treatment had a reduction in 60-day mortality to 50%, as against 81% in the control group.

The SCD-treated subjects who received more than 96 hours of treatment had a further reduction in mortality to 31% (p < 0.012).

SeaStar Medical president and CEO Eric Schlorff said: “Hyperinflammation can be a devastating factor for severe Covid patients who develop multi-organ complications.

“This pilot study helps inform our upcoming pivotal study, which will examine how our immunomodulatory therapeutic treatment can be disease-agnostic in its efforts to return a pro-inflammatory immune system back to a reparative state.”

The company also stated that the SCD treatment in Covid-19 ICU patients with multiple organ failure showed an acceptable safety profile, with no serious adverse events associated with the device.